Apeiron Investment Group withdrew its nomination at Sensei Biotherapeutics
Key Summary: On November 2022, Apeiron Investment Group (11–14.5%) called for urgent action at the company, including possible liquidation, citing strategic missteps and value destruction. On March 9, 2023, it nominated three directors but later withdrew its slate after the company agreed to repurchase its shares at $1.58 each.
Members Only · Snowball Research
Continue reading this report
Unlock the full analysis, investor activity breakdown, and complete commentary.
Try first
Free Trial
Submit a request with your professional email address and we'll send you a sample report.